Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

21 May 2009

Evolution of bone disease in patients during the first 2 years after transplantation; a prospective single centre study

K Falkiewicz, M Boratyńska, S Zmonarski, A Milewicz, D Patrzałek, P Biecek, M Klinger

Ann Transplant 2009; 14(1): 34-35 :: ID: 880323

Abstract

Background: Post-transplant bone disease is caused by renal osteodystrophy
acquired during HD, immunosuppressive drugs and metabolic factors after transplantation. Aim: to examine bone mineral density (BMD) and to identify factors preventing bone loss in patients in the first 2 years post transplant.
Material/Methods: 90 renal allograft recipients (age 42.7±11.4 years), treated with cyclosporine/tacrolimus, azathioprine/MMF and prednisone were included in the study. BMD measurements in lumbar spine and femur (femoral neck, Ward's and Trochanteric region) were performed by DEXA in the third month
and every 6 months for 2 years after transplantation. Markers of bone remodelling (intact parathyroid hormone [iPTH], calcitriol, osteocalcine, carboxyterminal telopeptide of type-I collagen) were assayed on the third day, 1[sup]st[/sup] month and every 6 months.
Results: In the initial measurement, osteopenia was found in 35% in the lumbar region and 52% in femur; osteoporosis in 8.3% (according o the WHO classification). Prevalence of osteopenia increased during the first year, then decreased to initial value, but the frequency of osteoporosis did not change (8.3 vs. 6.0%). BMD and Z-score decreased during first and increased in the second year; 27% patients achieved initial values and 38% higher than initial values. BMD gain in lumbar spine and femur was found in patients with significantly higher calcitriol level during first six months (P<0.01); higher osteocalcin level (P<0.05); higher eGFR during 1 to 24 months and treated with tacrolimus. Improvement of lumbar BMD occurred in younger patients (38 vs. 46 years; P<0.027). BMD gain in femur correlated with higher level of iPTH from 1-12 months (P<0.01);. Patients treated with tacrolimus had significantly higher Z-score in lumbar spine and femur at 24 month in comparison to cyclosporine treatment (p<0.05).
Conclusions: Two years after transplantation >60% of patients showed stability or gain in the bone mass. Sufficient calcitriol level in early post transplant period, adequate iPTH, renal efficiency and tacrolimus treatment prevent progression of the post-transplant bone disease.

Keywords: Immunosuppression, Kidney Transplantation

Add Comment 0 Comments

In Press

08 Mar 2024 : Original article  

Association of Coronary Calcium Score on Cardiac PET During Pre-Kidney Transplant Assessment with Persisten...

Ann Transplant In Press; DOI: 10.12659/AOT.943532  

14 Mar 2024 : Original article  

Impact of Blood Products Transfusion on Patients in the Immediate Post-Lung Transplant Period: A Cohort Study

Ann Transplant In Press; DOI: 10.12659/AOT.943652  

14 Mar 2024 : Case report  

Treatment of Cavernous Transformation of Portal Vein Caused by Hepatic Cystic Echinococcosis Using Ex Vivo ...

Ann Transplant In Press; DOI: 10.12659/AOT.942358  

15 Mar 2024 : Review article  

Approaches and Challenges in the Current Management of Cytomegalovirus in Transplant Recipients: Highlighti...

Ann Transplant In Press; DOI: 10.12659/AOT.941185  

Most Viewed Current Articles

05 Apr 2022 : Original article  

Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver Transplantation

DOI :10.12659/AOT.935604

Ann Transplant 2022; 27:e935604

12 Jan 2022 : Original article  

Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...

DOI :10.12659/AOT.934738

Ann Transplant 2022; 27:e934738

22 Nov 2022 : Original article  

Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...

DOI :10.12659/AOT.937988

Ann Transplant 2022; 27:e937988

15 Mar 2022 : Case report  

Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...

DOI :10.12659/AOT.935860

Ann Transplant 2022; 27:e935860

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358